Publicacións en colaboración con investigadores/as de Hospital Universitario La Fe (21)

2024

  1. Effectiveness and safety of levodopa–entacapone–carbidopa infusion in Parkinson disease: A real-world data study

    European Journal of Neurology

  2. Huntington Disease Health Related Quality of Life, Function and Well Being: The Patient’s Perspective

    Neurology and Therapy

  3. Impact of the COVID-19 pandemic on implantation of cardiac implantable electronic devices and remote monitoring activations

    Revista Espanola de Cardiologia, Vol. 77, Núm. 3, pp. 243-253

2023

  1. Epidemiology of ataxia and hereditary spastic paraplegia in Spain: a cross-sectional study

    Neurologia, Vol. 38, Núm. 6, pp. 379-386

  2. Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life

    Journal of Parkinson's disease, Vol. 13, Núm. 3, pp. 379-402

2022

  1. Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives

    Pharmaceutics, Vol. 14, Núm. 3

  2. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience

    Cancers, Vol. 14, Núm. 7

2021

  1. Use of azacitidine or decitabine for the up‐front setting in acute myeloid leukaemia: A systematic review and meta‐analysis

    Cancers, Vol. 13, Núm. 22

2019

  1. Clinical and genetic characteristics of late-onset Huntington's disease

    Parkinsonism and Related Disorders, Vol. 61, pp. 101-105

2018

  1. Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study

    Journal of Huntington's Disease, Vol. 7, Núm. 3, pp. 209-222

2017

  1. Cognitive decline in Huntington's disease expansion gene carriers

    Cortex, Vol. 95, pp. 51-62

2016

  1. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global -clinical evaluations, serum biomarkers, genetic studies and neuroimaging- prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression

    BMC Neurology, Vol. 16, Núm. 1

  2. Geometrical measures obtained from pretreatment postcontrast T1 weighted mris predict survival benefits from bevacizumab in glioblastoma patients

    PLoS ONE, Vol. 11, Núm. 8

2015

  1. Relationship between Nutritional Status and the Severity of Huntington's Disease. A Spanish Multicenter Dietary Intake Study

    Journal of Huntington's Disease, Vol. 4, Núm. 1, pp. 75-85

2013

  1. Suicidal ideation in a European Huntington's disease population

    Journal of Affective Disorders, Vol. 151, Núm. 1, pp. 248-258

2012

  1. Discrepancies in reporting the CAG repeat lengths for Huntington’s disease

    European Journal of Human Genetics, Vol. 20, Núm. 1, pp. 20-26

2009

  1. Neuroprotección en la enfermedad de parkinson: Análisis a través de la metodología de informadores clave

    Neurologia, Vol. 24, Núm. 2, pp. 113-124

2006

  1. A longitudinal study of patients with Parkinson's disease (ELEP): Aims and methodology

    Revista de Neurologia, Vol. 42, Núm. 6, pp. 360-365

  2. Creación y protocolo de seguimiento longitudinal de una cohorte multipropósito de pacientes con enfermedad de Parkinson de reciente diagnóstico: Proyecto VIP

    Revista de Neurologia, Vol. 43, Núm. 6, pp. 366-373

  3. Global versus factor-related impression of severity in Parkinson's disease: A new clinimetric index (CISI-PD)

    Movement Disorders, Vol. 21, Núm. 2, pp. 208-214